Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 1.00 |
| ▸ | CTSB | P07858 | 3/20 | 1.00 |
| ▸ | CAPN9 | O14815 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CTSG | P08311 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 2/20 | 0.66 |
| ▸ | CTSH | P09668 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 1/20 | 0.66 |
| ▸ | CTSC | P53634 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-64C SCHEMBL1121089 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL14067670 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10750447 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL3281530 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10933522 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL16982381 | 0.94 | CAPN1 (0.89) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL1807396 | 0.92 | CAPN1 (0.86) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL20643960 | 0.92 | CAPN1 (0.85) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL12653866 | 0.90 | CAPN1 (0.81) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL12904682 | 0.90 | CAPN1 (0.81) | CAPN1CTSBCAPN9MAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624336-B2 | In-vitro embryonic culture medium comprising an inhibitor of cathepsin L and the use of the same in embryo cryopreservation | BEIJING UNIVERSITY OF AGRICULTURE (CN) | 2020-04-21 | — | — | US | disclosed |
| US-20180160677-A1 | IN-VITRO EMBRYONIC CULTURE MEDIUM COMPRISING AN INHIBITOR OF CATHEPSIN L AND THE USE OF THE SAME IN EMBRYO CRYOPRESERVATION | BEIJING UNIVERSITY OF AGRICULTURE (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20060234276-A1 | Methods of treatment of type 2 diabetes | POLONSKY KENNETH S | 2006-10-19 | — | — | US | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020150896-A1 | Diagnosis and treatment of diabetes; obtain nucleotide sequence sample from tissue, detect polymorphism, presence of polymorphsm indicates diabetes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-17 | — | — | US | disclosed |
| US-6235481-B1 | Polynucleotides encoding calpain 10 | ARCH DEVELOPMENT CORPORATION & BOARD OF REGENTS | 2001-05-22 | — | — | US | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180160677-A1 | IN-VITRO EMBRYONIC CULTURE MEDIUM COMPRISING AN INHIBITOR OF CATHEPSIN L AND THE USE OF THE SAME IN EMBRYO CRYOPRESERVATION | CTSD, CTSL, CTSE | CAPN1 185/4885CTSB 5/4885CAPN9 84/4885 |
| US-10624336-B2 | In-vitro embryonic culture medium comprising an inhibitor of cathepsin L and the use of the same in embryo cryopreservation | CTSD, CTSL, CTSE | CAPN1 185/4885CTSB 5/4885CAPN9 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.